Amicus Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
March 01, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Cowen...
Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates
February 24, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
Galafold® Revenue Growth of 17% YoY to $306M in 2021 Galafold Global Sales Growing at Double-Digits (15-20%) with $350M-$365M in 2022 U.S. and EU Regulatory Filings Under Review and Launch...
Amicus Therapeutics to Announce Full-Year 2021 Financial Results on February 24, 2022
February 10, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February 24, 2022...
Amicus Therapeutics Announces Presentations and Posters at the 18th Annual WORLDSymposium™ 2022
February 07, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for...
Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance
January 10, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
Full-Year 2021 Galafold® Revenue of ~$306M, Representing 17% YoY Growth Expect Double-Digit Growth (15-20%) of 2022 Galafold Revenue with $350M-$365M in Global Sales U.S. and EU Regulatory Reviews...
Amicus Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference, being held...
European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease
December 03, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the European Medicines Agency (EMA) validated the Marketing Authorization Applications (MAA)...
Amicus Therapeutics to Present at the 4th Annual Evercore ISI HealthCONx Virtual Conference
November 24, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the 4th...
Amicus Therapeutics Announces Presentations at the 14th International Congress of Inborn Errors of Metabolism
November 22, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters for presentation at the 14th International Congress of Inborn Errors of...
The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease
November 18, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
Peer Reviewed Results from PROPEL Show Treatment with AT-GAA Provided Clinically Meaningful Improvements Over Standard of Care, including ERT Experienced Patients with High Unmet Need AT-GAA Deemed...